1 Medical Oncology department, Faculty of Medicine and Pharmacy of Casablanca, Morocco.
2 Internal Medicine department, Faculty of Medicine, University of Kinshasa, DRC.
3 Hematology and Medical Oncology department, Poissy Intercommunal Hospital Center, France.
World Journal of Advanced Research and Reviews, 2025, 27(02), 812-817
Article DOI: 10.30574/wjarr.2025.27.2.2931
Received on 06 July 2025; revised on 09 August; accepted on 12 August 2025
Background: Solid organ transplant recipients face a higher risk of cutaneous squamous cell carcinoma (cSCC) due to long-term immunosuppression. Managing metastatic cSCC in these patients is challenging because immune checkpoint inhibitors (ICIs) may cause graft rejection.
Case Presentation: A 67-year-old male heart transplant recipient developed multiple cSCCs with lung metastases during his illness. After surgery and radiotherapy, disease progression prompted systemic therapy with carboplatin and cetuximab. The patient achieved a complete metabolic response after seven cycles, with no graft rejection or severe side effects. Cetuximab maintenance therapy sustained the response.
Conclusion: Cetuximab offers a safe and effective treatment for advanced cSCC in heart transplant recipients, avoiding the risks of ICIs. This case shows that Cetuximab can be a good alternative treatment.
Cutaneous squamous cell carcinoma; Heart transplantation; Immunosuppression; Cetuximab
Preview Article PDF
Serge Emmanuel Bambule, Francia Holguin, Hubert Pheulpin, Pierre Zuech, Larisa Martanovschi, Gabriela Tossen and Geraldine Salmeron. Cetuximab-based management of metastatic cutaneous squamous cell carcinoma in a heart transplant recipient: A case report and literature review. World Journal of Advanced Research and Reviews, 2025, 27(2), 812-817. Article DOI: https://doi.org/10.30574/wjarr.2025.27.2.2931